Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gwo Ho"'
Autor:
Jessica W. Y. Wu, Sudiksha Dand, Lachlan Doig, Anthony T. Papenfuss, Clare L. Scott, Gwo Ho, Joshua D. Ooi
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point i
Externí odkaz:
https://doaj.org/article/94bdad1e60b94e84a1d00b55e7f346f3
Autor:
Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G. Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100939- (2021)
Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is an aromatase inhibitor in combination with a cyclin dependant kinase (CDK) 4/6 inhibitor. Frequently, these patients req
Externí odkaz:
https://doaj.org/article/7d95fe7dcfc74a4ba56a3404e5209bde
Autor:
Jixuan Gao, MoonSun Jung, Rebekka T. Williams, Danica Hui, Amanda J. Russell, Andrea J. Naim, Alvin Kamili, Molly Clifton, Angelika Bongers, Chelsea Mayoh, Gwo Ho, Clare L. Scott, Wendy Jessup, Michelle Haber, Murray D. Norris, Michelle J. Henderson, on behalf of Australian Ovarian Cancer Study
Publikováno v:
Cancers, Vol 14, Iss 8, p 1878 (2022)
Background: Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy with over 80% of cases already disseminated at diagnosis and facing a dismal five-year survival rate of 35%. EOC cells often spread to the greater omentum where
Externí odkaz:
https://doaj.org/article/309943b0c0a94d9d915568cbc9872776
Autor:
Gill Kruss, Jennifer Tan, Ranjana Srivastava, Steven David, Gwo Ho, Marion Harris, Lachlan McDowell, Gerard G Hanna, Daphne Day, Michelle White, Shom Goel
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 1, Pp 100939-(2021)
Translational Oncology, Vol 14, Iss 1, Pp 100939-(2021)
Highlights 5• CDK 4/6 inhibitors are commonly used in patients with advanced hormone receptor positive breast cancer. 5• Many patients receive palliative radiotherapy for symptomatic disease concomitantly with a CDK 4/6 inhibitor. 5• There is a
Autor:
Clare Hampson, David B. Stevens, Kathryn Alsop, Orla McNally, Victoria Francis, Gillian Mitchell, David E. Gyorki, Grant A. McArthur, Mikolaj Medon, Ismael A. Vergara, Gwo Ho, Scott Williams, Prudence A. Francis, Benjamin Solomon, Clare G Fedele, Nicole M. Haynes, Kate Strachan, Sumitra Ananda, Amy Haffenden, Erin Tidball, Jodie Leditschke, Mila Volchek, Odette Spruyt, Mitchell G. Lawrence, Peter Savas, Stephen Cordner, Mohammed Madadin, Renea A. Taylor, Samantha E. Boyle, Eva Vidacs, Shahneen Sandhu, Linda Mileshkin, Sue Shanley, Jan Pyman, Monique Topp, Rufaro Diana Jaravaza, Gail P. Risbridger, Melissa Papargiris, Ricky W. Johnstone, Hong Wang, Ravindra Samaranayake, Mark Shackleton, Anthony T. Papenfuss, Heather Thorne, Sarah-Jane Dawson, Clare L. Scott, Christopher Angel, Shirley Carvosso, Anne Hamilton, Paul Waring, Sherene Loi, Christopher P. Mintoff, Gisela Mir Arnau, Lisa Devereux, Sameera A. Gunawardena, David Ranson, Julene Hallo, Zhi Ling Teo, Patricia C. M. O’Brien, Gregory Young, David D.L. Bowtell, Elizabeth L. Christie
Publikováno v:
Nature biotechnology. 34(10)
Conference
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.